Dona Childers
Primary Care · Rome, GANPI 1245271022
Payments from drug & device makers
Across 45 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$118
- Dexcom, Inc.$113
- Abbott$110
- Boehringer Ingelheim$84
- AstraZeneca$73
- Sanofi-aventis U.S. LLC$56
- plus $322 from 13 others
What the payments were for
- Food & beverage$84697%
- Other$303%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $118 |
| Dexcom, Inc. | 4 | $113 |
| Abbott | 5 | $110 |
| Boehringer Ingelheim | 4 | $84 |
| AstraZeneca(2 entities) | 4 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Tandem Diabetes Care, Inc. | 3 | $43 |
| Medtronic | 2 | $43 |
| Zealand Pharma US, Inc. | 2 | $43 |
| BD | 1 | $28 |
| Antares Pharma, Inc. | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Lantheus Medical Imaging, Inc. | 1 | $14 |
| Rhythm Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$876 in reported general payments places this provider in the 60th percentile of 235 primary care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 463 | $577,594 |
| MounjaroTirzepatide | 309 | $413,153 |
| FarxigaDapagliflozin Propanediol | 293 | $270,221 |
| JardianceEmpagliflozin | 217 | $215,005 |
| Tresiba Flextouch U-100Insulin Degludec | 298 | $199,237 |
| Tresiba Flextouch U-200Insulin Degludec | 112 | $170,739 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $123,892 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 152 | $113,237 |
| Humalog Kwikpen U-200Insulin Lispro | 62 | $107,507 |
| Humalog Kwikpen U-100Insulin Lispro | 286 | $88,794 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 85 | $65,611 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $65,442 |
| RybelsusSemaglutide | 51 | $62,888 |
| Novolog FlexpenInsulin Aspart | 180 | $55,657 |
| TrulicityDulaglutide | 40 | $51,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $15 | $500,289484 claims |
| AstraZenecaFarxiga | $73 | $270,221293 claims |
| Boehringer IngelheimJardiance, Tradjenta | $84 | $230,291241 claims |
| Sanofi-aventis U.S. LLCLantus | $56 | $12,23799 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 235 primary care providers in Georgia.
Other primary care in Rome
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
- Sarah NewGrovetown$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.